We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+30.01%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.1B
AUM Growth
+$358M
Cap. Flow
-$161M
Cap. Flow %
-5.18%
Top 10 Hldgs %
35.61%
Holding
108
New
34
Increased
17
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$63.9M
2
MRK icon
Merck
MRK
+$61.9M
3
CI icon
Cigna
CI
+$60.7M
4
CGON icon
CG Oncology
CGON
+$59.4M
5
ISRG icon
Intuitive Surgical
ISRG
+$53.3M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$81.9M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$65.2M
3
IMGN
Immunogen Inc
IMGN
+$54.2M
4
BHVN icon
Biohaven
BHVN
+$53.1M
5
ZTS icon
Zoetis
ZTS
+$47.4M

Sector Composition

Rank Sector Weight
1 Healthcare 90.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
51
Vaxcyte
PCVX
$7.88B
$19.4M 0.63%
284,000
-286,137
-50% -$19.8M
IMCR icon
52
Immunocore
IMCR
$1.7B
$18.6M 0.6%
286,400
-13,800
-5% -$947K
PHAT icon
53
Phathom Pharmaceuticals
PHAT
$930M
$18.4M 0.59%
1,735,000
+13,420
+0.8% +$114K
MCK icon
54
McKesson
MCK
$104B
$17.9M 0.58%
33,300
-52,200
-61% -$26.5M
VERA icon
55
Vera Therapeutics
VERA
$2.39B
$16.5M 0.53%
+383,500
New +$13.7M
IMVT icon
56
Immunovant
IMVT
$7.99B
$16.3M 0.53%
505,000
+260,000
+106% +$9.49M
PRVA icon
57
Privia Health
PRVA
$3.13B
$15M 0.48%
764,200
-522,800
-41% -$11M
JANX icon
58
Janux Therapeutics
JANX
$915M
$14.5M 0.47%
+384,245
New +$8.37M
HELP
59
Cybin Inc
HELP
$471M
$14.4M 0.47%
+918,000
New +$13.3M
COLL icon
60
Collegium Pharmaceutical
COLL
$1.16B
$14M 0.45%
361,400
+37
+0% +$1.29K
PRME icon
61
Prime Medicine
PRME
$558M
$13.9M 0.45%
+1,990,000
New +$15.1M
KROS icon
62
Keros Therapeutics
KROS
$199M
$13.9M 0.45%
+209,700
New +$12.4M
ATXS
63
DELISTED
Astria Therapeutics
ATXS
$13.8M 0.45%
+982,000
New +$12.2M
ACIU icon
64
AC Immune
ACIU
$236M
$13.2M 0.43%
4,470,000
+920
+0% +$3.3K
KPTI icon
65
Karyopharm Therapeutics
KPTI
$161M
$12.5M 0.4%
553,238
– –
IMUX icon
66
Immunic
IMUX
$182M
$11.8M 0.38%
+890,297
New +$11.6M
CYTK icon
67
Cytokinetics
CYTK
$10.8B
$11.6M 0.38%
+166,000
New +$12.8M
RDNT icon
68
RadNet
RDNT
$4.97B
$11.6M 0.37%
+238,000
New +$9.59M
ESTA icon
69
Establishment Labs
ESTA
$2.7B
$11.5M 0.37%
+225,000
New +$9.03M
NAMS icon
70
NewAmsterdam Pharma
NAMS
$3.27B
$11.2M 0.36%
+475,000
New +$9.64M
ACAD icon
71
Acadia Pharmaceuticals
ACAD
$4.45B
$10.9M 0.35%
+588,500
New +$14.6M
AZN icon
72
AstraZeneca
AZN
$267B
$10.8M 0.35%
+80,000
New +$10.6M
SYRS
73
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.95M 0.29%
1,673,538
– –
GPCR icon
74
CALL
Structure Therapeutics
GPCR
$3.4B
$6.43M 0.21%
150,000
-450,000
-75% -$19M
IONS icon
75
Ionis Pharmaceuticals
IONS
$9.14B
$5.64M 0.18%
+130,000
New +$6.2M
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2024 Portfolio in Review

As of Q1 2024, Avidity Partners Management held 108 positions worth $3.1B, up 13% from $2.74B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Avidity Partners Management withdrew a net $161M in Q1 2024, closing 18 positions and reducing 30 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $65.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 95% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Illumina worth $63.7M.

  • Avidity Partners Management's largest Q1 2024 buy was Illumina: 477,095 shares worth $63.7M.
  • Avidity Partners Management added most to Intuitive Surgical in Q1 2024, an estimated $53.3M increase.
  • Avidity Partners Management's biggest Q1 2024 reduction was Thermo Fisher Scientific, cutting an estimated $81.9M.
  • Avidity Partners Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $65.2M.
  • Avidity Partners Management's ten largest holdings make up 36% of its $3.1B portfolio in Q1 2024.
  • Avidity Partners Management opened 34 new positions and closed 18 in Q1 2024.
  • Avidity Partners Management's portfolio value rose 13% quarter-over-quarter to $3.1B.

Based on Avidity Partners Management's 13F filing for Q1 2024, filed 15 May 2024.